[Indication of acemetacin in dermatological diseases (author's transl)]

In an open clinical study the anti-inflammatory effect and tolerability of the new non-steroidal drug, [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil) were investigated on 12 female and 10 male patients aged between 20 and 67 years and suffering from the following syndromes: vasculitis, thrombophlebitis, erythematodes cutaneus, morbus Reiter, atopic dermatitis, non-specific prostatitis, periarteriitis nodosa, pemphigus vulgaris and dermatitis herpetiformis Duhring. Although the number of patients treated with the anti-inflammatory agent, acemetacin, was relatively small it was established that for in correct indications acemetacin had a good analgesic effect and reduced the consumption of cortison. Particularly interesting was the fact that no side effects occurred in any of the patients.